The Fucose-M annose Ligand (FML) 
Visceral leishmaniasis or kala-azar is a chronic and frequently lethal disease, caused by parasites of the Leishmania donovani complex. The disease is characterized by fever, malaise, loss of weight, hepatomegaly, splenomegaly, anemia, leukopenia, h y p e rg a m m a g lu b u lin e m ia and p ro g re s s iv e suppression o f the cellular immune response. Kalaazar is often fatal if untreated after the onset of sym ptom s. F urtherm ore, chem oterapy shows several undesirable colateral effects. The total number o f Leishmania infected people all over the world is being estimated in twelve millions. Five hundred thousand o f these cases, each year, correspond to visceral leishmaniasis25. This number is probably underestimate since an accurate and uniform early diagnose o f disease has not yet been established. Visceral leishmaniasis is spreading out in the W orld due to the increased resistance of parasites to chemoterapy and o f insect vectors to insecticides41. InBrazil, the disease is disseminating from the North and North-East regions o f the country and has recently been described in the State o f Rio de Janeiro, previously considered as not endemic20.
The current diagnostic in endemic and epidemic areas is still based on clinical analysis and identification o f parasites in bone-marrow aspirates. This very invasive method can give positive results in cases of advanced kala-azar. The cure o f the disease cannot be monitored, and preclinical patients are not detected, their clinical evolution is not followed-up, and they are a potential reservoir of the disease in endemic areas. Anti -Leishmania circulating antibodies can be detected in human serum soon after infection: they attain high titers with the evolution o f the disease and progressively Tropical 29:153-163, 1996. disappear after its treatm ent. The sorologycal diagnosis o f kala-azar has been proposed as an alternative by several works, based on antigens that show d ifferen t degrees o f p u rificatio n , and developping assays with diverse sensitivity and specifficity ranges5 32 35 38 . The stability o f these antigens has also been discussed32. Nevertheless, a non invassive method o f monitorization o f the disease was not yet not available in Brazilian Public Health Services.
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In fe c te d m o n o c y te s , as w e ll as, p o ly m o rp h o n u c le a r n e u tr o p h ile s 7 19 and eosinophiles9 w ere described in the blood, as potential carriers o f L. donovani parasites from the skin to viscera and bone marrow. In older studies19 1, and in some recent reports on human kala-azar22, the presence o f infective parasites in the secreta o f the upper respiratory and digestive tracts, as well as in urine and faeces were cited. Only occasionally, inoculation o f leishmaniasis by the transfusional via were cited10. Recent indirect evidences support the need o f the study o f the blood mediated contamination with kala-azar in humans. Leishmania tropica was identified in bone marrow of american soldiers returning from Operation Desert Storm with viscerotropic leishmaniasis, and for this reason all individuals that traveled to that region were recommended to be deferred as blood donors12. Notwithstanding, the existence o f a blood-mediated contamination is up to now not admitted as a potential danger for leishmanial infections, and no control o f blood is performed for the detection o f leishmaniasis in blood banks, even in regions reported to be endemic for kala-azar, and expected to harbor a large num ber of subjects with subclinical infection.
The analysis o f the protective potential of Leishmanial antigens to cutaneous leishmaniasis in murine models has been the focus o f detailed studies. The W orld Health Organization encouraged the development o f vaccines for leishmaniasis, using total or partially identified parasite lysates and crude antigens, that could induce a clear prophylactic immune response24. This kind of vaccine has shown to be effective against cutaneous leishmaniasis1121. The vaccines derived from whole killed Leishm ania are in study in Brazil (L . amazonensis), Iran (L. major) and Venezuela (L. mexicana and L. braziliensis) 25 . However, for human visceral leishmaniasis, no vaccine is up to now available. Only few studies on immunization against Leishmania donovani have been undertaken in the murine model, using total parasites26 18 14 or purified antigens17.
In recent studies, we described the isolation of the FM L (Fucose M annose Ligand) of L. donovani promastigotes, a complex glycoproteic fraction that strongly inhibits promastigote27 and amastigote infection o f murine macrophages29. Its proteic moiety is mainly composed o f acidic and apolar aminoacid residues. Among its neutral sugar com ponents, fucose (10% ), m annose (47% ), g a la c to se (1 2 % ) and g lu c o se (3 0 % ) w ere described27. FM L developped a species-speciffic effect on the inhibition o f promastigote uptake by macrophages in vitro21. This is a potent antigen for rabbits, hamsters and mice283130. Its main antigenic fraction is a 36kD glycoprotein, recognized by most mouse IgG anti-FM L monoclonal antibodies, and present at the surface o f both the promastigote and amastigote forms o f L. donovani parasites29. The protective potential o f FM L on visceral leishmaniasis was analyzed in the isogenic CBhamster model31. W e studied the effect o f three intraperitoneal weekly doses o f FM L ( 100/xg) in saponin (100/xg), followed by an intracardiac injection of 107amastigotes. Protection was speciffic and highly significant (87.7% , p < 0 .0 1 ) in the enhancement of anti-FM L antibodies titers, o f the sp len o c y te p ro life ra tiv e re sp o n se , and the intradermal delayed hypersensitivity reaction to antigen, as well as in the decrease o f the parasite burden in spleen and o f splenom egaly31. An analogous study in the inbred balb/c mice model showed an average o f 84.2% (pCO .O O l) o f protection in antibody titers, splenocyte in vitro proliferation and liver parasitic load30.
In the present study we report the use o f the FM L antigen in diagnosis, p ro g n o sis32 and tra n s fu s io n a l c o n tro l o f h u m a n v is c e ra l leishmaniasis, monitoring the epidemic and endemic disease in Public Health Services o f Natal, Rio Grande do Norte, Brazil. This work shows the results obtained with the implementation o f the FMLELISA assay in the routine o f the laboratory sorologycal screening o f the Hospital de Doenças Infecciosas Giselda Trigueiro and the Centro de Hematologia e Hemoterapia-HEM ONORTE, with
A new tool in diagnosis, prognosis, transfusional control and vaccination against hum an kala-azar. R evista da Sociedade B rasileira de M edicina Tropical 29:153-163, 1996. the support o f the Fundação Nacional de Saúde, FN S. Furtherm ore, prelim inary results o f the analysis o f the FM Lvaccine in the outbred swiss albino mouse model, are described.
M ATERIAL AND METHODS
H u m a n sera A total o f 462 sera was analyzed in this study. A series o f 149 sera was collected by the Fundação Nacional de Saúde do Rio Grande do Norte, in the peri-urban area o f Natal, RN (North East Brazil), a focus o f a recent outbreak o f kala-azar. Ten o f the sera in this series came from subjects that had a patent kala-azar at the time o f serum collection. A series o f 26 sera o f kala-azar patients, before and during their treatment, was obtained at the Hospital de Doenças Infecciosas Giselda Trigueiro, Natal. All the 36 patients with clinical symptoms o f acute kala-azar (loss o f w eight, lym phadenopathy, hepatomegaly and/or splenomegaly, and fever) were submitted to bone m arrow aspiration. Parasitologic analysis confirmed the presence o f Leishmania amastigotes in the Giemsa-stained smears. After the serum collection, patients were submitted to antiLeishmania treatment. Thirty five sera o f patients that have had kala-azar w ere collected at least three months after the end o f the treatment with antimonials o r am photericin-B , during their clinical and serological follow-up32.
Twenty one persons with no patent signs of disease, neighbors and relatives of kala-azar patients, or owners of dogs with L. donovani infection, were also included in the study. We also analyzed the reactivity with FM L o f 21 sera of patients with cutaneous or mucocutaneous leishmaniasis from Rio de Janeiro and Minas Gerais states, obtained from Dr. S.M . Coutinho, Fundação Oswaldo Cruz, (Rio de Janeiro), 22 sera o f fully characterized patients with chronic Chagas disease from Bambui, M inas Gerais, and 18 sera from healthy adult blood donors from the Hospital Universitário Clementino FragaFilho, Universidade Federal do Riode Janeiro, that were screened and considered negative for Chagas disease, HIV I and II, hepatitis, and syphilis32. For differential control diagnosis, sera o f patients with fever and/or hepatosplenomegaly due to Paracoccidioides brasiliensis infections (1), lymphoma (2), typhus (1) and hemophagocytic disease (1) were obtained from the Departamento de Doenças Infecciosas, U FRJ, and Departamento de Pediatria UERJ, Rio de Janeiro, RJ.
A series o f 171 sera o f volunteer blood donors was obtained from the blood bank Centro de Hematologia e Hemoterapia-HEM ONORTE, and tested for their reactivity w ith FM L. Informed consent for this study was obtained from all the subjects included in this study. Titration o f normal human, kala-azar, Chagas' disease and cutaneous leishmaniasis patient's sera pools against FM L antigen was performed in order to establish the optimal antigen concentration. The micro-ELISA method was done as described32, using FM L diluted in carbonate buffer (pH 9.6), to sensitize flat-bottom 96-well plates (Haemobag, Ribeirão Preto, SP, Brazil). A ntibodies w ere detected by peroxidase-labeled protein-A (Sigma, St Louis, MO). Reaction was developed with Ophenyldiamine (Sigma), interrupted with IN sulfuric acid, and monitored at 492nm. Sera were analyzed by double blind tests, in triplicates, and results expressed as mean values. Positive and negative control sera were included in each test. The absorbance values o f sera were compared at 1:100. The cut o ff limit between the normal sera from a non-endem ic area and sera o f patients w ith parasitologically confirmed kala-azar, was identified using the Youden's J index43. S ignificance o f the differences between groups o f sera was established by a standard t test.
W estern Blot analysis FM L was submitted to SDS-PAGE under reducing conditions, in 10% slab "baby" gels and transferred to nitrocellulose. Strips were incubated with human sera diluted in blocking buffer, overnight at 4°C , washed and developed with peroxidaselabeled protein-A followed by diaminobenzidine (Sigma). 
Vaccination assays

2,5
month old swiss albino female mice were obtained from the Bioterio Central, Instituto de M icrobiologia da U FR J. Groups of 6-8 females were immunized w ith three either subcutaneous or intraperitoneal doses o f 150/xg FM L and 100 /xg saponin (Riedel-de Haen, Seelze, Germany) in 0.2m l sterile 0.95% saline, with weekly interval. Saline and saponin treated controls were included. Seven days after immunization, sera were collected and animals were challenged by intravenous inj ection o f 2 x 107 L. donovani amastigotes, obtained from infected ham ster's spleens6. Animals were sacrificed by etherization, 15 days after infection, and their liver and spleen parasite-load was monitored in Leishman-Donovan Units o f Stauber of Giemsa stained imprintings (L D U =num ber of amastigotes/ 1000 cell nuclei x mg organ weight). Sera o f animals before and after infection were analyzed by ELISA using 2/ig FM L/w ell and reacted with a Peroxidase labeled anti-mouse IgG (Sigma, Co.). ELISA results were expressed as scores (sum o f all absorbances at 492nm, up to the end-point titer)32. Statistical comparison o f the groups was done by the Student t test.
RESULTS
Standardization o f ELISA experiments was done using FM L in dilutions from 0.03 to 2p.g per well, reacted with pools o f normal human sera from a non-endemic area, sera o f patients w ith kala-azar, tegumentar leishmaniasis and Chagas disease, in dilution 1:2000. The results presented in the Figure  1 , indicated the antigen concentration o f 0 . 125/xg / well as the highest that gave no unspecific reaction. All the studied samples were titered and scored in this condition.
The individual absorbance values in FM L-ELISA assay for 1:100 diluted sera are represented in Figure 2A . The mean value o f Abs 1:100 (X + SE = 0.452 ± 0.038) o f patients w ith acute kalaazar was significantly different from the one of the normal subjects o f a nonendemic area (p < < 0.001). Eight standard error values separated 153-163, 1996. the two means. The use o f mean value + 2SD in the FML-ELISA assay attain the maximal Youden v a lu e = l, corresponding to the absence o f fa lse p o sitive or fa ls e negative results (cut off value = 0.204). Sera o f patients with chronic Chagas disease sh o w ed , as ex p ected from sta n d a rd iz a tio n experiments, a very reduced reactivity (Abs 1:100 mean value 0.149). In the endemic area, ( Figure  2B ). the FM L-ELISA assay functioned as a highly discriminating tool. It allowed to distinguish the non-reactive sera from the endemic area (NE) (n = 86), from the group of subjects without any sign of leishmanial infection but reactive with FML (RE) (n = 59). We interpret these subjects as a subclinical but activeLeishmania infection, in view o f their clinical evolution. During the ten months following the first study of 41 sera from the kalaazar outbreak region, nine o f the inhabitants o f the studied endemic area spontaneously searched medical treatment for the severe disease (NKA). Kala-azar was diagnosed by identification o f amastigotes in the bone-marrow aspirate. Among these, six had had high titers of anti-FM L antibodies and the highest titers had been observed in two patients that eventually died of severe kala-azar. During the same period, at our knowledge, no subjects with negative reaction to FM L developed kala-azar. Consequently, among 41 sera that had shown high or low reactivity with FM L but had not clinical signs o f kala-azar, more than 20% developed the overt disease in the ten month period. This num ber is probably underestimated, since a full clinical and serological survey of the same area has not been completed32. Sera o f patients with fever and hepatosplenomegaly due to P aracoccidioides b ra silien sis infection (1), lym phom a (2) and hemophagocytic disease (1) gave also negative results in the FM L-ELISA assay. These results determined 100% sensitivty and 96 % specificity.
A random monitoring o f anti-FM L reactivity among 171 volunteer blood donors at the blood bank Centro de H em atologia e Hem oterapia-HEM O N O RTE, Natal, was performed, testing an average o f 24.4 diary donor samples, for a period o f seven consecutive days. The results obtained are summarized in Table 1 . The FM L-ELISA test showed the clearly positive reaction for 8 donors. The other 163 samples showed no reactivity (X + S E = 0 .1 3 8 + 0.002). This values represent a total o f 5% o f samples and were distributed attaining even 17% in a single day, no one o f which had a positive reaction for Chagas's disease, hepatites, HIV nor syphilis or a decreased hematocrite value. Conversely, among the nonreactive donors, two cases o f hepatites B were detected indicating that also in this assay the FM L-ELISA showed to be highly specific.
Since the FM L components can be separated by electrophoresis, we have analyzed by Western Blot the reactivity o f human sera with FM L (Figure 3 ). Figure  4A . Before the infection a pronounced speciffic response to FM L (p < 0.001 ) was detected in animals immunized w ith FM L and saponin, higher by the intraperitoneal than the subcutaneous route. After the infection, both group of mice showed an increased response whereas no response was detected in any control group. Taken Ligand) o /L eish m a n ia don ovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against  human kala-azar. Revista d a Sociedade Brasileira de M edicina Tropical 29:153-163, 1996. toguether these results represent an average o f 80.0 % increase in speciffic antibody response and a 85.5% protection in reduction of parasite liver burden. Although the humoral response was higher in the case o f intraperitoneal administration, no signifficant difference between the vias was shown in what concern to protective effect.
DISCUSSION
ELISA tests using crude native antigens are usually done in dilutions o f 2 to 5/ig/w ell15 l6. In an improved ELISA assay, the recombinant GP63 antigen of L. chagasi was used in concentration of 1 /xg/well35 39. The FM L is thus a very sensitive antigen, and standard ELISA tests can be done in dilutions increased by an order of magnitude. This sensitivity can be probably advantageously used in development o f rapid and automated tests for kalaazar. This property o f FM Lcan be possibly attributed to its glycoproteic nature. Previous studies have attributed the species-specific characteristics of Leishmania glycoconjugates to their glycidic moiety28.
The presented results indicate that assays using FM L can be highly sensitive and specific in diagnosis of kala-azar. This antigen can clearly separate visceral leishmaniasis from all the other closely related tegumentar infections caused by parasite of the gen u s L eishm ania, w ith the sen sitiv ity comparable to those reported for recombinant antigens35 39. M oreover, this antigen can identify inhabitants o f endem ic areas with a potential subclinical infection, and point out those with a high risk o f evolution towards the overt severe disease. It can be also used to follow-up of the parasitologic cure. D ifferent form previously reported data2, the FM L antigen isolated from an African strain o f L. donovani was accurate in d ia g n o s is o f S o u th A m erican v isc e ra l leishmaniasis, representing apparently a tool that can be used throughout the diagnostics o f diseases caused by the L. donovani complex.
Two cases o f a positive reaction o f FM L with sera o f a patient without overt kala-azar were observed. The first was a patient with chronic disseminated muco-cutaneous leishmaniasis. This serum had high titers o f IgG and IgM antibodies against L. braziliensis, but the parasite could not be isolated nor characterized. The second was from a patient with Chagas's disease. In both examples the possibility o f a concomitant infection with L. donovani could not be ruled out since visceral leishmaniasis was also endemic in these regions. These two positive reactions are at present, of difficult interpretation. Their presence has decreased the specificity o f the assay to 96% . The FM L antigen developed equal levels o f sensitivity and specificity than the recombinant antigen used by Bums et al (1993)8. However, different from the recombinant antigen, FM L is a a glycoproteic complex and its long lasting stability makes o f it a good candidate for work in field assays. W e were able to use the same batch for period over two years with no signifficant changes in its performance.The FML-ELISA test is now being used as a new tool for diagnosis, prognosis, cure survey o f visceral leishmaniasis and it is used as an alternative to bone marrow punction in several human cases with no false negative or positive results. The test is performed routinely in the cited Hospital and Blood bank services. Furthermore a clinical and epidemical survey o f perypherical areas o f Natal, using the FML-ELISA test is underway.
In this study we described the presence o f L. Finally, the reported results indicate that FM L may be a potential candidate for vaccination in visceral leishm aniasis. Both intraperitoneal or subcutaneous immunizations were effective. These results are particularly signifficant in view of the outbred nature o f the experimental model. Indeed a high intragroup variation was expected. This protective effect o f FM L and saponin is in agree to previous evidences o f the protective potential against experimental visceral leishmaniasis in CB hamsters and Balb/c mice30 31. In our conditions, saponin showed nor toxic neither unspeciffic effects. Its use as adjuvant was compared to Corynebacterium parvum, Freund Adjuvant, Alhydrogel, Bordetella pertussis and M uramyl dipeptide and considered to be advantageous4. In agreement with our results, saponin has been previously shown to be a good p o te n tia to r o f a n ti-p ro to z o a n im m unity in experimental vaccines against T cruzp1. However, saponins are discriminated as adjuvant because of their hemolytic properties3. For this reason, we started the comparative analysis o f the hemolytic and ajuvant potential o f different kind of saponins. Using the purified antigen DP72 for immunization of balb/c mice against L. donovani infection, a protective effect o f the same order o f magnitude was reported16 33. However, in those works, for protection or lym phocyte proliferation assays, respectively, after sensitization with the antigen, theanimals received different dosesofpromastigotes. It is consequently not clear if the described effects were due only to D P72 adm inistration or to promastigote injection or to both o f them. Two other antigens of Leishmania, extensively studied were candidates for vaccination against cutaneous leishmaniasis in mice, however, it was recently shown that GP63 is unable to induce lymphocyte proliferation in human leishmaniasis23 and that the ability o f LPG to induce a protective response in mice is due to contaminant proteins or glycoproteins, called LPG associated p ro tein s (L P G A P )17. Furthermore subcutaneous LPG vaccination against m u rin e te g u m e n ta r le is h m a n ia s is by th e subcutaneous route showed to induce an increase of lesion size, instead o f protection13. Recently, the immunization with one o f the LPGAP flagellar proteins, present in a wide range o f Leishmania species and in African trypanosom es, in the recombinant form, stimulates primed lymphocytes to proliferate in vitro40. The use o f FM L of Leishmania donovani and o f its components in sorologycal screening for visceral leishmaniasis shows high sensitivity, specificity, stability and comparatively easier performance. Its use in Blood banks would improve the quality control to prevent blood borne infections. Furtherm ore it showed a signifficant potential on experimental vaccination against kala-azar. The study o f the molecular aspects related to the described FM L potentials is under progress. 
